Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation

BACKGROUND AND PURPOSES: Erythropoietin (EPO) has been shown to protect against myocardial infarction in animal studies by activating phosphatidylinositol-3 kinase (PI3K)/Akt and ERK1/2. However these pro-survival pathways are impaired in the diabetic heart. We investigated the ability of EPO to pro...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Mudalagiri, N R, Mocanu, M M, Di Salvo, C, Kolvekar, S, Hayward, M, Yap, J, Keogh, B, Yellon, D M
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2007
Témata:
Research Papers
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2199395/
https://ncbi.nlm.nih.gov/pubmed/17952111
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjp.0707461
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky